These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 9226319

  • 1. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP, Pollack A, Zagars GK.
    Int J Radiat Oncol Biol Phys; 1997 May 01; 38(2):327-33. PubMed ID: 9226319
    [Abstract] [Full Text] [Related]

  • 2. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
    Pollack A, Lankford S, Zagars GK, Babaian RJ.
    Cancer; 1996 Apr 15; 77(8):1515-23. PubMed ID: 8608537
    [Abstract] [Full Text] [Related]

  • 3. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.
    Int J Radiat Oncol Biol Phys; 2002 Mar 01; 52(3):664-73. PubMed ID: 11849788
    [Abstract] [Full Text] [Related]

  • 4. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.
    Pollack A, Smith LG, von Eschenbach AC.
    Int J Radiat Oncol Biol Phys; 2000 Sep 01; 48(2):507-12. PubMed ID: 10974469
    [Abstract] [Full Text] [Related]

  • 5. Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.
    Kestin LL, Goldstein NS, Vicini FA, Martinez AA.
    J Urol; 2002 Nov 01; 168(5):1994-9. PubMed ID: 12394693
    [Abstract] [Full Text] [Related]

  • 6. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA, Stock RG, Stone N.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):645-53. PubMed ID: 14529768
    [Abstract] [Full Text] [Related]

  • 7. Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.
    Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.
    Int J Radiat Oncol Biol Phys; 2002 Mar 15; 52(4):888-92. PubMed ID: 11958880
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dose response in prostate cancer with 8-12 years' follow-up.
    Hanks GE, Hanlon AL, Epstein B, Horwitz EM.
    Int J Radiat Oncol Biol Phys; 2002 Oct 01; 54(2):427-35. PubMed ID: 12243818
    [Abstract] [Full Text] [Related]

  • 10. Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer.
    Ingenito AC, Ennis RD, Hsu IC, Begg MD, Benson MC, Schiff PB.
    Urology; 1997 Jul 01; 50(1):73-8. PubMed ID: 9218022
    [Abstract] [Full Text] [Related]

  • 11. Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
    Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA.
    Int J Radiat Oncol Biol Phys; 2003 Nov 01; 57(3):629-34. PubMed ID: 14529766
    [Abstract] [Full Text] [Related]

  • 12. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK, Pollack A, von Eschenbach AC.
    Int J Radiat Oncol Biol Phys; 1995 Aug 30; 33(1):23-35. PubMed ID: 7543892
    [Abstract] [Full Text] [Related]

  • 13. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
    Anderson PR, Hanlon AL, Patchefsky A, Al-Saleem T, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1998 Jul 15; 41(5):1087-92. PubMed ID: 9719119
    [Abstract] [Full Text] [Related]

  • 14. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 15. External beam radiotherapy dose response of prostate cancer.
    Pollack A, Zagars GK.
    Int J Radiat Oncol Biol Phys; 1997 Dec 01; 39(5):1011-8. PubMed ID: 9392538
    [Abstract] [Full Text] [Related]

  • 16. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.
    BJU Int; 2012 Jul 01; 110(1):36-42. PubMed ID: 22085203
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis.
    Hung AY, Levy L, Kuban DA.
    Cancer J; 2002 Nov 01; 8(6):440-4. PubMed ID: 12500852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.